App-Quantinova.ai

Effect of covid-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension

Christian Battersby - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pulmonary arterial hypertension

N/A

Association between immune checkpoint inhibitors and heart failure hospitalisations: a population-based self-controlled case series

Gary Tse - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Remote personalisation of pulmonary arterial hypertension therapy and application of a remote physiological risk score

Frances Varian - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pulmonary arterial hypertension

N/A

Gastrointestinal bleeding and cancer in patients with heart failure and iron deficiency

Joe Cuthbert - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Gastrointestinal bleeding

N/A

Myocardial fibrosis activity in ischaemic and non-ischaemic cardiomyopathy

Shruti Joshi - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

N/A

Medication non-adherence assessed using liquid chromatography tandem mass spectrometry in patients with chronic heart failure

shirley sze - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Angiotensin II

What matters to older patients living with chronic heart failure and frailty: a conversation with patients and informal caregivers

Sunanthiny Krishnan - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

The trajectory of nutrition status and its association with clinical outcomes and quality of life in patients with heart failure

shirley sze - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Cardiac contractility index identifies systolic dysfunction in preserved ejection fraction heart failure

Sam Straw - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

N/A

Effect of intravenous iron (ferric derisomaltose) on haemoglobin and clinical events according to age in patients with heart failure and iron deficiency in a randomised trial (ironman)

Iain Squire - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Frailty trajectory over one year among ambulatory patients with heart failure

AHMAD AIMAN AZRI AHMAD ZUBAIRI - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Risk of infection with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency in the uk: a prespecified analysis of the ironman trial

Paul Foley - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Design and validation of a physiological risk score for pulmonary arterial hypertension (pah)

Jennifer Middleton - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Physiological detection of clinical worsening and therapeutic response using implanted remote technologies in pah

Jennifer Middleton - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Prevalence of silent myocardial infarction in patients with left ventricular systolic dysfunction and associations with dysglycaemia

Peter Harrison - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Myocardial infarction

N/A

Maternal myocardial alterations during pregnancy and their recovery twelve months’ post-partum in women with pregnancies complicated by gestational diabetes or preeclampsia- a single centre, longitudinal cohort study

Sharmaine Thirunavukarasu - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Gestational Diabetes

Mofezolac

Myocardial stress perfusion and energetics improves in patients with type 2 diabetes after treatment with a glucagon like peptide-1 receptor agonist (liraglutide)- a randomised, single centre, open label, cross-over drug trial

Amrit Chowdhary - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

Liraglutide

Two-dimensional and four-dimensional velocity imaging quantified mitral regurgitation is associated with left ventricular remodelling post mitral valve surgery

Miroslawa Gorecka - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Mitral valve regurgitation

N/A

Non-invasive assessment of stroke work using cardiac magnetic resonance imaging

Gareth Matthews - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Pulmonary arterial hypertension

N/A

The diagnostic and prognostic value of left ventricular ejection fraction corrected for myocardial remodelling

Amit Kaura - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

EF-40

Filters

45280 Abstracts